Skip to main content
icometrix logo

icometrix

Acquired

Leuven, Belgium

  • Neuroimaging
  • Series A
  • Alzheimer's and dementia

icometrix develops AI-powered brain imaging solutions that analyze MRI and CT scans to support the diagnosis and monitoring of neurological conditions. Its clinically validated tools provide automated, quantitative insights for clinicians and researchers, and icometrix is now a GE HealthCare company.

Raised
$18M
May 2019
Series A
Investors
5
Employees
51–100

reccy insights

Recent highlights

In 2026, the Multiple Sclerosis Association of America selected icometrix as the Improving Lives Benefit Corporate Honoree, recognizing its AI-based brain-imaging software in support of the multiple sclerosis community. The benefit took place on May 7, 2026. This recognition reinforces the company’s focus on applying quantitative MRI analysis to neurological care, particularly multiple sclerosis. A notable earlier product milestone came on November 14, 2024, when icobrain aria was announced as an AI-driven MRI solution authorized for detecting, measuring, and grading amyloid-related imaging abnormalities in Alzheimer’s patients receiving amyloid-targeting therapies.

Written by reccy's AI from company sites, press and funding records · updated Nov 2026

What makes icometrix distinct

  1. 01Automates detection and quantification of brain structures and lesions to support clinical decision-making.
  2. 02Addresses a range of neurological conditions, including multiple sclerosis, Alzheimer’s disease, stroke, traumatic brain injury, epilepsy, Parkinson’s disease, and brain tumors.
  3. 03Combines clinical validation with regulatory clearances, including FDA-cleared solutions and CE-marked products.
  4. 04Designed to integrate with hospital workflows, connecting MRI scanners, PACS, and EMR systems through icobridge.
  5. 05Builds its products around a patient-centered goal of improving care for people affected by brain disorders.

Technology & products5

  • icobrain

    AI-driven software for quantitative analysis of brain MRI scans to assist in diagnosing and monitoring neurological disorders.

  • icobrain aria

    AI software for detecting, measuring, and grading amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients undergoing amyloid-targeting therapies.

  • icobrain dm

    AI software supporting early detection and differential diagnosis of dementias through volumetric analysis of brain MRI scans.

Recent updates2

  • May 7, 2026Award

    2026 Improving Lives Benefit Corporate Honoree

  • Nov 14, 2024Product launch

    icobrain aria was announced as an AI software solution for detecting, measuring, and grading ARIA in Alzheimer’s patients, supporting safety monitoring during amyloid-beta-targeting therapies.

    prnewswire.com

Funding

$18M disclosed
5 investors

Similar companies

About icometrix

Products
icobrain, icobrain aria, icobrain dm, icobrain ep, icobrain tumor
Leadership
Wim Hecke, CEODirk Smeets, Chief Technology OfficerJan Verheyden, COO
Focus areas
NeuroTechnology, digital health, diagnostics, AI/ML, medical devices, medical imaging, neurology
Headquarters
Leuven, Belgium
Employees
51–100
Status
Acquired
Patents granted
6
Trademarks
7